Upregulation of some immune checkpoints, such as CD27, CD274 (PD-L1), CTLA4, IDO1, and PDCD1 (PD-1), were reported to be associated with poor survival and recurrence in gliomas (40–43). This evidence concerns the gene CD27 and glioma.